These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. When should the β-blocker window in cirrhosis close? Ge PS; Runyon BA Gastroenterology; 2014 Jun; 146(7):1597-9. PubMed ID: 24768679 [No Abstract] [Full Text] [Related]
5. Once spontaneous bacterial peritonitis develops, discontinue nonselective beta blockers permanently. A proposed practice change update. Tahan V Turk J Gastroenterol; 2014 Apr; 25(2):232. PubMed ID: 25003694 [No Abstract] [Full Text] [Related]
6. Nonselective β blockers increase risk for hepatorenal syndrome and death in patients with cirrhosis and spontaneous bacterial peritonitis. Mandorfer M; Bota S; Schwabl P; Bucsics T; Pfisterer N; Kruzik M; Hagmann M; Blacky A; Ferlitsch A; Sieghart W; Trauner M; Peck-Radosavljevic M; Reiberger T Gastroenterology; 2014 Jun; 146(7):1680-90.e1. PubMed ID: 24631577 [TBL] [Abstract][Full Text] [Related]
7. β-blockers and refractory ascites in cirrhosis: the message of a team of true scientists. Angeli P J Hepatol; 2011 Oct; 55(4):743-4. PubMed ID: 21396970 [No Abstract] [Full Text] [Related]
8. Targeting the gut-liver axis in cirrhosis: antibiotics and non-selective β-blockers. Madsen BS; Havelund T; Krag A Adv Ther; 2013 Jul; 30(7):659-70. PubMed ID: 23881723 [TBL] [Abstract][Full Text] [Related]
9. Targeting circulatory dysfunction in cirrhosis: terlipressin and the hepatorenal syndrome. Testro AG; Angus PW J Gastroenterol Hepatol; 2009 Nov; 24(11):1707-9. PubMed ID: 20136956 [No Abstract] [Full Text] [Related]
10. [Physiopathology of refractory ascites and the hepatorenal syndrome]. Arroyo V Nefrologia; 2002; 22 Suppl 5():41-6. PubMed ID: 12107916 [No Abstract] [Full Text] [Related]
11. Development of ascites in compensated cirrhosis with severe portal hypertension treated with β-blockers. Hernández-Gea V; Aracil C; Colomo A; Garupera I; Poca M; Torras X; Miñana J; Guarner C; Villanueva C Am J Gastroenterol; 2012 Mar; 107(3):418-27. PubMed ID: 22334252 [TBL] [Abstract][Full Text] [Related]
12. Benefits of Beta blockade beyond bleeding prophylaxis and the role of adherence. Thalheimer U; Christie J; Burroughs AK Am J Gastroenterol; 2012 Oct; 107(10):1593. PubMed ID: 23034623 [No Abstract] [Full Text] [Related]
13. Letter: non-selective beta-blockers in cirrhosis-effect beyond portal hypertension. Authors' reply. Dunne P; Young D; Chuah CS; Hayes P; Tripathi D; Leithead J; Smith L; Gaya D; Forrest E; Stanley AJ Aliment Pharmacol Ther; 2022 Jul; 56(1):186-187. PubMed ID: 35689317 [No Abstract] [Full Text] [Related]
14. Beta-blockers to prevent gastroesophageal varices in cirrhosis. Post AB N Engl J Med; 2006 Mar; 354(12):1318-20; author reply 1318-20. PubMed ID: 16554538 [No Abstract] [Full Text] [Related]
15. Hemodynamic response to pharmacological treatment of portal hypertension and long-term prognosis of cirrhosis. Abraldes JG; Tarantino I; Turnes J; Garcia-Pagan JC; Rodés J; Bosch J Hepatology; 2003 Apr; 37(4):902-8. PubMed ID: 12668985 [TBL] [Abstract][Full Text] [Related]